跳至主要内容
临床试验/NCT05786950
NCT05786950已完成不适用

Neural Respiratory Drive of Patients With Chronic Obstructive Pulmonary Disease

The First Affiliated Hospital of Guangzhou Medical University1 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2023年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
44
试验地点
1
主要终点
the change of the neural respiratory drive

研究概览

简要总结

To investigate the relationship among the neural respiratory drive (NRD), the sensation of the dyspnea and the effect of the bronchodilator on each stage COPD patients.

详细描述

Different stage COPD subjects were recruited. Administration of bronchodilators was prohibited 24 hours prior to the experiment. After the application of topical anesthesia (10% xylocaine) the subject was asked to swallow the multipair esophageal electrode catheter through the nose into their right position. At the first period, the stable signals of spontaneous breathing (about 10 minutes) were collected as the baseline data. At the second period, each subject inhaled compound ipratropium bromide solution (3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany). A multi-pair esophageal electrode catheter with 10 coils that provided five pairs of electrodes was used to obtain the NRD signals. All NRD signals the were recorded before and after the compound ipratropium bromide solution was inhaled (about 10 minutes). The subjects scored their comfort sensation with a visual analog scale (VAS) ranging from 0 (best) to 10 (worst) at each period.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
35 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The diagnosis of COPD was made according to the global initiative for chronic obstructive lung disease (GOLD) guideline.

排除标准

  • (1) Malignancy (2)Severe cardiovascular diseases (3)Neuromuscular and chest wall deformity (4) Cardiovascular instability (hypotension, arrhythmias, myocardial infarction) (5) Change in mental status; uncooperative patients (6) Extreme obesity (7)renal failure and severe blood electrolyte disturbances (8) Asthma-

研究组 & 干预措施

bronchodilators

Experimental

compound ipratropium bromide solution (3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany)

干预措施: compound ipratropium bromide solution (3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany) (Drug)

结局指标

主要结局

the change of the neural respiratory drive

时间窗: 20 minutes

the change of the neural respiratory drive

次要结局

  • comfort sensation(20 minutes)

研究者

发起方
The First Affiliated Hospital of Guangzhou Medical University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Zhang Jianheng

Professor

The First Affiliated Hospital of Guangzhou Medical University

研究点 (1)

Loading locations...

相似试验